<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304757</url>
  </required_header>
  <id_info>
    <org_study_id>SanghaiXinhua</org_study_id>
    <nct_id>NCT02304757</nct_id>
  </id_info>
  <brief_title>99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis</brief_title>
  <official_title>Prospective Trial of 99Tc-MDP and Fosamax in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis Treated With Supraphysiological Doses of Thyroid Hormone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of&#xD;
      levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of&#xD;
      osteoporosis. Therefore, the investigators try to investigate the effects of&#xD;
      99Tc-MDP,alendronate sodium in postmenopausal women with DTC under TSH suppression and&#xD;
      osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Differentiated thyroid cancer (DTC) has become one of the most common endocrine malignancies.&#xD;
      According to American Thyroid Association (ATA) and Chinese Thyroid Association (CTA), most&#xD;
      of DTC patients undergo total or near total thyroidectomy, radioiodine ablation and TSH&#xD;
      (thyroid stimulating hormone) suppression. Osteoporosis (OS) and fractures are important&#xD;
      comorbidities in patients with DTC, with potential negative impact on quality of life (QOL)&#xD;
      and survival. The main determinant of skeletal fragility in DTC is the TSH suppression.&#xD;
      Postmenopausal women with DTC under TSH suppression therapy are more vulnerable to OS.&#xD;
      Technetium-99 methylene diphosphonate (99Tc-MDP) is a decay product of 99mTc-MDP (used for&#xD;
      bone scintigraphy) and a novel bisphosphonates, which has been used in China for diseases&#xD;
      like rheumatoid arthritis (RA), ankylosing spondylitis (AS) and osteochondral lesions of the&#xD;
      talus, etc. However, as a member of bisphosphates, little attention has been paid to its&#xD;
      anti-OS effect for DTC under TSH suppression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with OS were divided into 99Tc-MDP and fosamax treatment groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change of Bone Mineral Density in Lumbar and Hip</measure>
    <time_frame>baseline, 6 months, and 12 months</time_frame>
    <description>Percent change of bone mineral density in lumbar and hip by dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>bone turnover markers including C-telopeptides of type I collagen (CTX), Type I N-procollagen terminal propeptide(PINP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life by 36-item Short Form Health Status Survey Questionnaire (0-100)</measure>
    <time_frame>baseline, 6 months, and 12 months</time_frame>
    <description>The health related quality of life was measured by 36-item Short Form Health Status Survey questionnaire (SF-36). The minimum and maximum values were 0 and 100, respectively. Higher scores mean a better a better outcome.&#xD;
The questionnaire includes 36 items that can be classified into the following eight health status subscales: Physical Functioning, Physical Role Limitations, Bodily Pain, General Health Perception, Vitality, Social Functioning, Emotional Role Limitations, and Mental Health. A standardized Physical Component Summary and a standardized mental component score were calculated. The physical component summary and mental component summary represent the deviation from the reference population in Sweden. Higher scores mean a better a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>6 months, and 12 months</time_frame>
    <description>A transient rash and phlebitis, gastrointestinal reaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>99Tc-MDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosamax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70mg po every week for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99Tc-MDP</intervention_name>
    <description>99Tc-MDP, H20000218</description>
    <arm_group_label>99Tc-MDP</arm_group_label>
    <other_name>Yunke,Technetium [99Tc] Methylenediphosphonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosamax</intervention_name>
    <description>H20080172</description>
    <arm_group_label>Fosamax</arm_group_label>
    <other_name>alendronate sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1) They were pathologically diagnosed with DTC including papillary or follicular&#xD;
        carcinoma. (2) They received a near total thyroidectomy and radioiodine treatment. (3) TSH&#xD;
        suppression should be at least one year before the study. (4) Bone mineral density (BMD) in&#xD;
        lumbar spine and/or hip was tested by Dual-energy X-ray absorptiometry (DXA) at baseline, 6&#xD;
        month (m) and/or 12m follow up. 5) The diagnosis of osteoporosis was T-score ≤-2.5 SD at&#xD;
        the lumbar spine, or hip.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients having medications for osteoporosis before TSH suppression treatment;&#xD;
&#xD;
          2. secondary osteoporosis ;&#xD;
&#xD;
          3. severe liver or kidney disease;&#xD;
&#xD;
          4. myelosuppression;&#xD;
&#xD;
          5. digestive disease;&#xD;
&#xD;
          6. long term use of immunosuppressive agent, estrogen or estrogen receptor modulators.&#xD;
             This study was approved by the Institutional Review Board of Hospital Research Ethics.&#xD;
             All the patients were fully acquainted with their treatment and consented to&#xD;
             participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chao Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuclear Medicine Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <results_first_submitted>April 22, 2021</results_first_submitted>
  <results_first_submitted_qc>September 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2021</results_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chao Ma</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>differentiated thyroid cancer</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>thyroid stimulating hormone suppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Methylene diphosphonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02304757/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled in three centers (Tenth People's Hospital of Tongji University, Shanghai No. 4 People's Hospital and Xinhua Hospital School of Medicine Shanghai Jiaotong University) from January 2015 to December 2019.</recruitment_details>
      <pre_assignment_details>In the total of 142 included patients, 70 were treated with 99Tc-MDP and 72 were treated with Fosamax.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>99Tc-MDP</title>
          <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
        </group>
        <group group_id="P2">
          <title>Fosamax</title>
          <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>99Tc-MDP</title>
          <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
        </group>
        <group group_id="B2">
          <title>Fosamax</title>
          <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.29" spread="7.96"/>
                    <measurement group_id="B2" value="62.73" spread="7.24"/>
                    <measurement group_id="B3" value="63" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sex: Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM staging</title>
          <description>T1N0-1, indicated participants had tumor ≤2 cm in greatest dimension, and with (N1) or without (N0)metastasis to lymph node; T2N0-1, tumor size &gt;2 cm but ≤4 cm in greatest dimension, and with or without metastasis to lymph node; T3N0-1, tumor size &gt;4 cm, and with or without metastasis to lymph node; TxNX, indicated participants had unknown tumor size and unknown metastasis to lymph node; TxN0-1, indicated participants had unknown tumor size, and with or without metastasis to lymph node; T1-2Nx, tumor ≤2 cm(T1) or &gt;2 cm but ≤4 cm (T2), and unknown metastasis to lymph node.</description>
          <units>number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T1N0-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2N0-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3N0-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4N0-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TxNx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TxN0-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1-2Nx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change of Bone Mineral Density in Lumbar and Hip</title>
        <description>Percent change of bone mineral density in lumbar and hip by dual energy x-ray absorptiometry</description>
        <time_frame>baseline, 6 months, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>99Tc-MDP</title>
            <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
          </group>
          <group group_id="O2">
            <title>Fosamax</title>
            <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Bone Mineral Density in Lumbar and Hip</title>
          <description>Percent change of bone mineral density in lumbar and hip by dual energy x-ray absorptiometry</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change of lumbar spine at month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="6.6"/>
                    <measurement group_id="O2" value="3.2" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change of lumbar spine month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="10.9"/>
                    <measurement group_id="O2" value="5.1" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change of total hip at month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="7.7"/>
                    <measurement group_id="O2" value="4.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change of total hip at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="17"/>
                    <measurement group_id="O2" value="4.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Turnover Markers</title>
        <description>bone turnover markers including C-telopeptides of type I collagen (CTX), Type I N-procollagen terminal propeptide(PINP)</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>99Tc-MDP</title>
            <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
          </group>
          <group group_id="O2">
            <title>Fosamax</title>
            <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Markers</title>
          <description>bone turnover markers including C-telopeptides of type I collagen (CTX), Type I N-procollagen terminal propeptide(PINP)</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PINP before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7725" spread="14.74802"/>
                    <measurement group_id="O2" value="29.255" spread="29.46603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PINP at 12months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6422" spread="20.56123"/>
                    <measurement group_id="O2" value="20.56123" spread="25.34437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4657" spread="0.25277"/>
                    <measurement group_id="O2" value="0.1526" spread="0.14138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX at 12months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3707" spread="0.21062"/>
                    <measurement group_id="O2" value="0.1771" spread="0.16019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life by 36-item Short Form Health Status Survey Questionnaire (0-100)</title>
        <description>The health related quality of life was measured by 36-item Short Form Health Status Survey questionnaire (SF-36). The minimum and maximum values were 0 and 100, respectively. Higher scores mean a better a better outcome.&#xD;
The questionnaire includes 36 items that can be classified into the following eight health status subscales: Physical Functioning, Physical Role Limitations, Bodily Pain, General Health Perception, Vitality, Social Functioning, Emotional Role Limitations, and Mental Health. A standardized Physical Component Summary and a standardized mental component score were calculated. The physical component summary and mental component summary represent the deviation from the reference population in Sweden. Higher scores mean a better a better outcome.</description>
        <time_frame>baseline, 6 months, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>99Tc-MDP</title>
            <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
          </group>
          <group group_id="O2">
            <title>Fosamax</title>
            <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life by 36-item Short Form Health Status Survey Questionnaire (0-100)</title>
          <description>The health related quality of life was measured by 36-item Short Form Health Status Survey questionnaire (SF-36). The minimum and maximum values were 0 and 100, respectively. Higher scores mean a better a better outcome.&#xD;
The questionnaire includes 36 items that can be classified into the following eight health status subscales: Physical Functioning, Physical Role Limitations, Bodily Pain, General Health Perception, Vitality, Social Functioning, Emotional Role Limitations, and Mental Health. A standardized Physical Component Summary and a standardized mental component score were calculated. The physical component summary and mental component summary represent the deviation from the reference population in Sweden. Higher scores mean a better a better outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical component summary at baseline by 36-item Short Form Health Status Survey questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="17.5" upper_limit="92.5"/>
                    <measurement group_id="O2" value="64.4" lower_limit="30.5" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary at 6months by 36-item Short Form Health Status Survey questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.587" lower_limit="14" upper_limit="100"/>
                    <measurement group_id="O2" value="69.09" lower_limit="25.5" upper_limit="94.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary at 12months by 36-item Short Form Health Status Survey questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="30.25" upper_limit="94.25"/>
                    <measurement group_id="O2" value="68" lower_limit="40" upper_limit="92.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score at baseline by 36-item Short Form Health Status Survey questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" lower_limit="19.38" upper_limit="100"/>
                    <measurement group_id="O2" value="65.7" lower_limit="34.88" upper_limit="95.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score at 6months by 36-item Short Form Health Status Survey questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0359" lower_limit="14" upper_limit="100"/>
                    <measurement group_id="O2" value="66.24" lower_limit="39.38" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score at 12months by 36-item Short Form Health Status Survey questionnaire (0-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2645" lower_limit="15" upper_limit="100"/>
                    <measurement group_id="O2" value="67.087" lower_limit="37.75" upper_limit="92.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>A transient rash and phlebitis, gastrointestinal reaction.</description>
        <time_frame>6 months, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>99Tc-MDP</title>
            <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
          </group>
          <group group_id="O2">
            <title>Fosamax</title>
            <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>A transient rash and phlebitis, gastrointestinal reaction.</description>
          <units>side effects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dyspepsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected at 1year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>99Tc-MDP</title>
          <description>15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.&#xD;
99Tc-MDP: 99Tc-MDP, H20000218</description>
        </group>
        <group group_id="E2">
          <title>Fosamax</title>
          <description>70mg po every week for 12 months.&#xD;
Alendronate Sodium: H20080172</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper gastrointestinal (GI) adverse events</sub_title>
                <description>In the 6/72 patients with GI adverse events treated with alendronate, 2 cases had abdominal pain, 4 had dyspepsia.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="72" subjects_affected="6" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chao Ma</name_or_title>
      <organization>Tenth People's Hospital of Tongji University</organization>
      <phone>02125078593 ext 86</phone>
      <email>mc_7419@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

